Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Radway-Bright, E. L.
Right arrow Articles by Isenberg, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Radway-Bright, E. L.
Right arrow Articles by Isenberg, D. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology, Vol 38, 591-601, Copyright © 1999 by British Society for Rheumatology

REVIEWS

Animal models of the antiphospholipid syndrome

EL Radway-Bright, M Inanc and DA Isenberg
Bloomsbury Rheumatology Unit, Department of Medicine, University College London, UK.

The antiphospholipid antibody syndrome (APS) is characterized by thrombocytopenia, recurrent thromboembolic phenomena and recurrent fetal loss, in association with anticardiolipin antibodies (aCL) and/or lupus anticoagulant (LA). Owing to the ethical and practical restrictions of experimentation on humans, we have to look to animal experimentation to broaden our knowledge of the pathogenesis and management of APS. Work has been carried out predominantly on strains of naive mice in which APS has been induced, passively and actively, using autoantibodies, autoantigens and other antigens. Studies of autoimmune-prone mice and naive rabbits are present in the literature, to a lesser degree. We review the various animal models of the pathogenesis of APS, whether spontaneous or induced, which have been developed over the years. Although several of the models have provided insights into the relationship between antiphospholipid antibodies and fetal loss, very few give guidance to explain the link with thrombosis. Novel or experimental therapeutic regimens have to be tested on appropriate animal models before any kind of human clinical trials may proceed. The regimens devised thus far are also reviewed.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
S. Ferreira, D. P. D'Cruz, and G. R. V. Hughes
Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand?
Rheumatology, April 1, 2005; 44(4): 434 - 442.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
A N Mason, R A Mageed, and C G Mackworth-Young
The effects of a human IgM monoclonal anticardiolipin antibody on pregnancy in a transgenic mouse model
Lupus, April 1, 2001; 10(4): 289 - 294.
[Abstract] [PDF]

Home page
 Ann Rheum DisHome page
R H W M DERKSEN, P. G DE GROOT, H K NIEUWENHUIS, and G C M L CHRISTIAENS
How to treat women with antiphospholipid antibodies in pregnancy?
Ann Rheum Dis, January 1, 2001; 60(1): 1 - 3.
[Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.